Home > Haematology > EHA 2019 > Myeloid Malignancies > Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML

Presented By
Dr Alexander Perl, University of Pennsylvania, USA
Conference
EHA 2019
Trial
Phase 3, ADMIRAL
Dr Alexander Perl (University of Pennsylvania, USA) presented the data from the phase 3 ADMIRAL trial of gilteritinib, a selective FLT3 inhibitor, for relapsed or refractory (R/R) acute myeloid leukaemia (AML). Patients were randomised 2:1 to receive either gilteritinib or one of 4 standard salvage chemotherapy treatments. The investigators report favourable outcomes of gilteritinib observed in this trial with increased complete response rate and improved overall survival for R/R AML [1]. FLT3 mutations (FLT3MUT+) occur in approximately 30% of patients with AML and are often associated with poor survival. Results from the ADMIRAL trial show the median overall survival for R/R FLT3MUT+ AML patients who received gilteritinib was 9.3 months vs 5.6 months for patients who received salvage chemotherapy (HR 0.637; 95% CI 0.490-0.830; P=0.007); 1-year su...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on